Royal Bank Of Canada Karuna Therapeutics, Inc. Transaction History

Royal Bank Of Canada

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$161.01 - $317.85 $1.1 Million - $2.17 Million	6,830 Added 29.87%	29,693 $9.4 Million
Q3 2023 Nov 14, 2023	BUY	$164.66 - $218.08 $1.95 Million - $2.59 Million	11,862 Added 107.83%	22,863 $3.87 Million
Q2 2023 Aug 14, 2023	SELL	$176.32 - $240.22 $201,357 - $274,331	-1,142 Reduced 9.4%	11,001 $2.39 Million
Q1 2023 May 15, 2023	BUY	$161.33 - $204.36 $78,406 - $99,318	486 Added 4.17%	12,143 $2.21 Million
Q4 2022 Feb 14, 2023	BUY	$191.53 - $236.82 $1.25 Million - $1.55 Million	6,548 Added 128.17%	11,657 $2.29 Million
Q3 2022 Nov 14, 2022	BUY	$123.79 - $277.42 $605,580 - $1.36 Million	4,892 Added 2254.38%	5,109 $1.15 Million
Q2 2022 Aug 15, 2022	SELL	$93.97 - $143.33 $111,824 - $170,562	-1,190 Reduced 84.58%	217 $28,000
Q1 2022 May 16, 2022	SELL	$98.9 - $132.37 $362,567 - $485,268	-3,666 Reduced 72.26%	1,407 $178,000
Q4 2021 Feb 14, 2022	BUY	$110.64 - $159.4 $331,588 - $477,721	2,997 Added 144.36%	5,073 $665,000
Q3 2021 Nov 15, 2021	SELL	$101.2 - $125.87 $176,897 - $220,020	-1,748 Reduced 45.71%	2,076 $254,000
Q2 2021 Aug 16, 2021	BUY	$107.45 - $135.95 $410,888 - $519,872	3,824 New	3,824 $436,000

332K

Ticker KRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 33,965,000
Description
Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients wi...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.